Core Viewpoint - The company has submitted a CE mark registration application for its GeminiOne transcatheter edge-to-edge repair (TEER) system for treating mitral valve regurgitation, indicating steady progress in its global strategy [1] Group 1: Product Development - GeminiOne is an internally developed innovative TEER device featuring a unique sliding groove mechanical structure that maintains a small implant size and delivery system while achieving a longer grasping arm length [1] - The device includes innovative features such as an independent leaflet capture function to reduce surgical complexity, an automatic locking mechanism to prevent repeated locking and unlocking during the procedure, and a multi-angle release design to accommodate a wider range of anatomical structures [1] - The design of GeminiOne has been patented globally and has passed multiple freedom-to-operate analyses [1] Group 2: Regulatory Progress - As of the announcement date, the registration application for GeminiOne has been accepted by the National Medical Products Administration of the People's Republic of China and is currently under review [1] - Additionally, GeminiOne has received an investigational device exemption from the U.S. Food and Drug Administration to conduct early feasibility studies [1] - The company is actively advancing the registration process for this product in China and Europe, aiming to provide safe and effective treatment options for patients with mitral valve regurgitation as soon as possible [1]

Core Viewpoints - The company holds a leading position in the domestic heart valve intervention field, with TAVR products showing positive clinical feedback and rapid market share growth since commercialization [1][6] - The company has a comprehensive product pipeline in aortic, mitral, and tricuspid valve treatments, which continues to strengthen its leadership in the heart valve sector [1][6] - The company anticipates three major products to be approved and commercialized in China between the end of 2025 and 2026, contributing to a rapid recovery in overall performance [1][6] Event Summary - On December 5, 2025, the company announced that Chairman Dr. Zhang Yi plans to invest up to HKD 15 million in purchasing company shares on the open market [1] - This share buyback reflects Dr. Zhang's confidence in the company's long-term development potential and intrinsic value [1] Product Development and Pipeline - The company has made significant progress in its product pipeline, with multiple innovative products expected to achieve commercialization, including the GeminiOne transcatheter edge-to-edge repair system and the ReachTactile robotic-assisted TAVR system [2][3] - The TaurusTrio aortic valve replacement system, GeminiOne, and the non-glutaraldehyde cross-linked TAVR product TaurusNXT are expected to be approved and commercialized between late 2025 and 2026, driving revenue growth [2][3] Neurointervention Business - The company has successfully launched the YonFlow mesh stent and has entered multiple provincial markets, indicating strong commercialization potential [4] - The neurointervention business is expected to maintain rapid growth, with a profit margin exceeding 20% and ongoing product development [4] Financial Outlook - The company projects revenues of CNY 758 million, CNY 1.035 billion, and CNY 1.385 billion for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 23.17%, 36.46%, and 33.88% [6] - The net profit attributable to the parent company is expected to improve significantly, with projections of CNY -114 million, CNY 14 million, and CNY 129 million for the same years, reflecting substantial growth [6]